Skip to main content

Table 4 ABC length of sulforaphane (SF) exposure analysis

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

ABC variable

Intervention (SF)a

Non-exposure (PL)

N

F-statistic

p value

N

F-statistic

p value

Total score

 7 weeks

38

9.59

0.004

21

4.76

0.041

 15 weeks

34

12.74

0.001

18

2.02

0.166

 22 weeks

16

5.05

0.016

   

 30 weeks

12

2.22

0.156

   

Sqrt lethargyb

 7 weeks

38

1.55

0.221

21

2.94

0.102

 15 weeks

34

4.75

0.016

18

1.68

0.218

 22 weeks

16

4.20

0.028

   

 30 weeks

12

2.06

0.179

   

Sqrt irritability

 7 weeks

38

6.06

0.019

21

2.27

0.147

 15 weeks

34

9.27

0.001

18

0.87

0.436

 22 weeks

16

4.03

0.032

   

 30 weeks

12

2.06

0.179

   

Sqrt stereotypy

 7 weeks

38

4.85

0.034

21

1.74

0.202

 15 weeks

34

6.06

0.006

18

1.72

0.210

 22 weeks

16

1.22

0.343

   

 30 weeks

12

0.75

0.588

   

Hyperactivity

 7 weeks

38

9.62

0.004

21

10.15

0.005

 15 weeks

34

9.95

< 0.001

18

4.68

0.025

 22 weeks

16

5.36

0.013

   

 30 weeks

12

3.26

0.073

   

Inappropriate speech

 7 weeks

38

7.85

0.008

21

0.27

0.607

 15 weeks

33

4.11

0.026

18

0.11

0.894

 22 weeks

16

3.02

0.068

   

 30 weeks

12

1.95

0.196

   
  1. Bold signifies p < 0.05
  2. MANOVA test for repeated measures
  3. aN for SF group at 7 and 15 weeks includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
  4. bSqrt: Square root transformations were conducted on these biomarkers to achieve a more normal distribution
Back to article page

Molecular Autism

ISSN: 2040-2392